In case that this association between ILC3 and susceptibility to GVHD is further confirmed in future independent cohorts, supplying acute myeloid leukemia patients with IL‐22 or IL‐22‐producing ILC3 might be a mean to prevent GVHD. Here, IL22 is linked to graft versus host disease.